Strata Critical Medical (SRTA) Cash & Equivalents (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Cash & Equivalents data on file, last reported at $58.7 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $58.7 million, up 68.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.7 million (up 68.6% YoY), and the FY2025 annual result was $31.0 million, up 92.68% from the prior year.
• Cash & Equivalents climbed to $58.7 million in Q1 2026 per SRTA's latest filing, from $31.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $186.6 million in Q2 2022 and troughed at $263000.0 in Q3 2025.
• A 5-year average of $37.9 million and a median of $34.8 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 1572.24% in 2023, then slumped 98.69% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $3.1 million in 2022, then sank by 62.79% to $1.1 million in 2023, then jumped by 1300.0% to $16.1 million in 2024, then soared by 92.68% to $31.0 million in 2025, then jumped by 89.62% to $58.7 million in 2026.
• Business Quant data shows SRTA's Cash & Equivalents at $58.7 million in Q1 2026, $31.0 million in Q4 2025, and $263000.0 in Q3 2025.